Full-Time
Updated on 8/20/2026
Develops, manufactures, and sells animal vaccines
$82k - $118k/yr
H1B Sponsorship Available
Parsippany-Troy Hills, NJ, USA
Hybrid
Hybrid role with 50% on-site work; the posting also considers candidates in the Washington, DC area.
Bachelor's
See people who can refer or advise you
Zoetis creates medicines and vaccines to protect the health of companion animals and livestock. Its products include vaccines, anti-infectives, parasiticides, dermatology and other therapeutics, medicated feed additives, and diagnostics, sold through veterinarians, livestock producers, and pet owners. The company reaches customers in more than 100 countries and relies on big R&D and a global marketing network to bring new solutions to market. Its goal is to improve animal health worldwide by delivering science-based products and services that help care for animals and prevent disease.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parsippany-Troy Hills, New Jersey
Founded
1952
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Hybrid Work Options
Zoetis, an animal health company, has drawn attention from investor Michael Burry, who is long the stock according to Substack disclosures cited by media outlets. The shares have fallen roughly 40% this year and over 70% from their 2021 peak. Competition from Elanco and Merck in dermatology and parasite treatments has pressured results. In fiscal Q2 2026, revenue was roughly flat, with US sales down 7% whilst international revenue grew 6%. The stock now trades near 12 times forward earnings, compared with a historical average of 30 times. Zoetis maintains around 86% of the US pet skin drug market, with gross margins above 70%. Wall Street analysts remain mostly bullish, with consensus price targets suggesting roughly 70% upside potential.
Zoetis reported flat revenue of $2.47 billion in Q2, missing Wall Street estimates of $2.50 billion, though adjusted earnings per share of $1.87 slightly beat consensus. The animal health company faces intensifying competition in key Companion Animal categories and declining US veterinary clinic visits. CEO Kristin Peck noted that veterinary visits have declined across markets for multiple years, coinciding with price increases exceeding broader consumer inflation. The company's Livestock and Diagnostics segments showed resilience despite weakness in dermatology and parasiticides. Zoetis lowered its full-year revenue guidance to $9.22 billion from $9.82 billion, a 6.1% reduction, and cut adjusted EPS guidance to $6.20, down 10.5%. Operating margin fell to 37.4% from 39.1% year-on-year. Management indicated it is implementing temporary, targeted promotional actions rather than permanent price cuts to defend market share. Competitive pressures may persist into 2027.
Zoetis has appointed former GE Healthcare CFO Jay Saccaro to a newly created dual role as CFO and chief operating officer, effective 17 August. Saccaro, who spent three years at GE Healthcare and nine years as CFO at Baxter International Healthcare, will receive an annual base salary of $1 million, with eligibility for bonuses totalling 100% of his salary and long-term incentives worth $5 million. He will also receive a one-time restricted stock unit award valued at approximately $6.2 million and a cash award of $1.2 million. Current CFO Wetteny Joseph will transition to special advisor on 16 August, remaining in a non-executive role until February 2027 or an earlier agreed date. The appointment comes as the New Jersey-based animal health company seeks new growth opportunities amid economic headwinds.
Zoetis reported second-quarter 2026 adjusted earnings of $1.87 per share, beating the consensus estimate of $1.84. However, total revenues of $2.47 billion fell flat year over year and marginally missed expectations of $2.49 billion. US segment revenues declined 7% to $1.30 billion, driven by an 11% drop in companion animal product sales due to softer demand and increased competition. Livestock product sales in the US rose 23% to $222 million. International segment revenues increased 8% to $1.17 billion, supported by growth in parasiticides and livestock products. Zoetis cut its 2026 revenue guidance to $9.12-9.32 billion, reflecting expected operational growth of negative 1-3%. Year to date, shares have plunged 40%.
Zoetis reported Q2 2026 revenue of $2.5 billion, flat year-over-year and down 1% on an organic operational basis. Adjusted diluted earnings per share rose 4% to $1.87, whilst adjusted net income fell 2% to $781 million. The animal health company's global companion animal revenue declined 6% to $1.7 billion, with key dermatology products down 16% to $395 million. However, livestock revenue grew 11% to $731 million, driven by demand in cattle and poultry. International markets provided growth momentum, with revenue up 6% to $1.2 billion, whilst US revenue fell 7% to $1.3 billion. Companion animal diagnostics revenue increased 12% to $118 million. For full-year 2026, Zoetis expects revenue of $9.12 billion to $9.32 billion and adjusted diluted EPS of $6.15 to $6.25.